Daron Hakimian, Mushriq Al-Jazrawe, Niklas Rindtorff, Esteban Miglietta, Csaba Molnar, Ashley Ruehr, Nicole Ostrovsky, Elisabeth Abeyta, Steven Blum, Beth Cimini, Samuel Klempner, Jesse Boehm
We report an improved rapid ex vivo biosensor for evaluating therapeutic responses in patient-derived tumor and immune cells obtained from malignant ascites. Building on our previous platform, the system now enables granular, single-cell-level immune classification through integrated marker detection (CD3, CD14, CD16, CD45) combined with quantitative morphological profiling. This upgrade allows reliable identification of T cells, macrophages, and natural killer cells directly within the tumor microenvironment. By coupling immune-cell resolution with customizable drug panels, the biosensor provides a robust framework for assessing immune-modulatory agents and dissecting heterogeneous response patterns. These advances strengthen the platform's utility for guiding drug-selection strategies and advancing rapid, patient-specific therapeutic assessment.
